Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Chronic Lymphocytic Leukemia Clinical Trials

A listing of Chronic Lymphocytic Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (387) clinical trials

HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)

This study aims to determine the HEPLISAV-B hepatitis B vaccine efficacy in chronic lymphocytic leukemia (CLL) patients that are treatment naive or receiving Bruton s-tyrosine kinase inhibitor (BTK-I) therapy. Key Eligibility Criteria: Diagnosis of CLL Cohort 1: Treatment naive CLL patients Cohort 2: Subjects must be receiving ibrutinib monotherapy for ...


A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

This is a global, Phase 3, randomized study of zanubrutinib versus ibrutinib in approximately 400 patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The primary efficacy endpoint is overall response rate determined by independent central review. Patients will be randomized in a 1:1 manner to either zanubrutinib or ...


Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation

Primary Objective: Determine the proportion of patients with full donor T-cell chimerism at Day 28 following hematopoietic cell transplantation. Secondary Objectives: Determine the risk of disease progression, overall and event free survival, and non-relapse mortality, following treatment with TLI; ATG; and TBI. Determine the incidence of acute and chronic GVHD ...


CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

This is an open-label, single arm, dose escalation study in patients with relapsed or refractory CLL. Treatment will be administered on an outpatient basis and all patients will receive CYC065 over 4-hour infusion once every 2 weeks on Day 1 and Day 15 in combination with venetoclax. One treatment cycle ...


CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma

Patients with relapsed or refractory leukemia or lymphoma are often refractory to further chemotherapy. In this study, the investigators will attempt to use T cells obtained directly from the patient, which can be genetically engineered to express a fully human chimeric antigen receptor (CAR). The CAR used in this study ...


Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

PRIMARY OBJECTIVES: I. To determine the clinical activity of enasidenib mesylate (AG221, IDHIFA) in combination with azacitidine (AZA) for patients with relapsed/refractory acute myeloid leukemia is measured by overall response rate (ORR). SECONDARY OBJECTIVES: I. To determine duration of response, event-free survival (EFS), and overall survival (OS). II. To determine ...


Project to Improve Communication About Serious Illness - Pilot Study

This two-year pilot study will test whether a one-page "Jumpstart Form" will affect goals-of-care discussions in the hospital. This form will be provided to clinicians and will include patient-specific information about preferences for goals-of-care communication and for care, as well as tips to improve this communication. Jumpstart forms will also ...

Phase N/A

Safety and Efficacy of KTE-X19 in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia

The primary objective of this study is to evaluate the safety (Phase 1) and efficacy (Phase 2) of KTE-X19 in adults with relapsed/refractory chronic lymphocytic leukemia (r/r CLL).


A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

This is a two-part study comprised of a dose escalation part and a dose expansion part. In the dose escalation part single patient cohorts will be dosed until a single related toxicity of Grade 3 or a Dose Limiting Toxicity (DLT) is observed. If this occurs, the study will switch ...


A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting

The purpose of this study is to describe the 2-year retention rate of ibrutinib treatment for chronic lymphocytic leukemia (CLL) in Italian routine clinical practice.

Phase N/A